Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2023/10/27
-
Journal
-
Indian UGC (journal)
-
Refrences203
-
Citations3
-
Hristelina Ilieva
-
Mithila Vullaganti
-
Justin Kwan
Abstract
Cite
Ilieva, Hristelina, et al. “Advances in Molecular Pathology, Diagnosis, and Treatment of Amyotrophic Lateral Sclerosis”. BMJ, 2023, p. e075037, https://doi.org/10.1136/bmj-2023-075037.
Ilieva, H., Vullaganti, M., & Kwan, J. (2023). Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis. BMJ, e075037. https://doi.org/10.1136/bmj-2023-075037
Ilieva, Hristelina, Mithila Vullaganti, and Justin Kwan. “Advances in Molecular Pathology, Diagnosis, and Treatment of Amyotrophic Lateral Sclerosis”. BMJ, 2023, e075037. https://doi.org/10.1136/bmj-2023-075037.
Ilieva H, Vullaganti M, Kwan J. Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis. BMJ. 2023;:e075037.
Journal Categories
Medicine
Internal medicine
Medicine
Medicine (General)
You May Also Like
- How to communicate evidence to patients
- Distalgesic and its equivalents: time for action
- TPMT testing before azathioprine therapy?
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: A six‐month longitudinal study | Muscle & Nerve |
| 21 | 2010 |
| MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis | 2000 | |||
| Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis | Journal of Medical Genetics |
| 2020 | |
| 10.21203/rs.3.rs-386600/v1 | ||||
| White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis | Brain |
| 91 | 2011 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Fluid biomarkers for amyotrophic lateral sclerosis: a review | Molecular Neurodegeneration |
| 1 | 2024 |
| Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis | Translational Neurodegeneration |
| 2024 | |
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders | Cells |
| 2024 |
Citations Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system 2
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis and was published in 2024. The most recent citation comes from a 2024 study titled Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis. This article reached its peak citation in 2024, with 3 citations. It has been cited in 3 different journals, 100% of which are open access. Among related journals, the Translational Neurodegeneration cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.